Nonmuscle myosin light-chain kinase (MYLK) mediates increased lung vascular endothelial permeability in lipopolysaccharideinduced lung inflammatory injury, the chief cause of the acute respiratory distress syndrome. In a lung injury model, we demonstrate here that MYLK was also essential for neutrophil transmigration, but that this function was mostly independent of myosin II regulatory light chain, the only known substrate of MYLK. Instead, MYLK in neutrophils was required for the recruitment and activation of the tyrosine kinase Pyk2, which mediated full activation of b 2 integrins. Our results demonstrate that MYLK-mediated activation of b 2 integrins through Pyk2 links b 2 integrin signaling to the actin motile machinery of neutrophils.
Neutrophils are the first line of defense against invading micropathogens. To kill pathogens, neutrophils must first attach to the blood vessel wall, then transmigrate into tissue to reach the site of infection and consume pathogens by phagocytosis 1 . Therefore, pathogen-induced adhesion and migration of neutrophils are critical events in the innate immune response 2, 3 . In contrast, inappropriate sequestration of neutrophils in tissue coupled with their activation can also cause profound injury, such as that in sepsis-induced acute respiratory distress syndrome 4, 5 .
Myosin light-chain kinase (MYLK; A000026) is a calciumcalmodulin-dependent kinase that phosphorylates myosin II regulatory light chain (MLC), the substrate for MYLK 6, 7 . MYLK has two isoforms: smooth muscle (short form; 108-130 kilodaltons) and nonmuscle (long form; 210 kilodaltons) 8, 9 . Mice deficient in nonmuscle MYLK (Mylk -/-mice) are protected from endotoxin-induced lung injury and also have much better survival 10 . The protection in Mylk -/-mice may result from inhibition of the endothelial hyperpermeability response and impaired neutrophil transmigration and activation due to the loss of nonmuscle MYLK function. Nonmuscle MYLK has been shown to be pivotal in endothelial barrier disruption through the regulation of actomyosin contractility in endothelial cells 11, 12 . However, the function of nonmuscle MYLK in regulating neutrophil transmigration in the innate immune response has not been investigated.
Integrins are a family of transmembrane receptors for extracellular matrix proteins 13 . The b 2 integrins, the main integrins expressed in neutrophils and other leukocytes, are key effectors mediating the adhesion of neutrophils to endothelial cells during inflammation and other immune responses 14 . Integrins function not only as adhesive proteins but also as signaling molecules [13] [14] [15] [16] . Intracellular signals such as those stimulated by chemokine receptors activate integrins to an intermediate active state and induce the binding of integrins to their ligands in the extracellular matrix 17 . Integrin-matrix interactions in turn induce 'outside-in' signals that activate the tyrosine kinases c-Src, Syk and Pyk2 (also called Ptk2b; A001952) 18 , which promote actin polymerization, thereby reinforcing the integrincytoskeleton connection. This interaction leads to the full activation of integrins [18] [19] [20] [21] . Therefore, actin dynamics regulated by tyrosine kinases are important for b 2 integrin-mediated adhesion of neutrophils to the endothelium 14, [22] [23] [24] .
MYLK is involved in integrin-mediated attachment of the leading edge to the matrix in T cells and adhesion disassembly in fibroblasts through the regulation of myosin II (refs. 25,26) . In addition to its kinase activity, MYLK interacts with cytoskeletal components such as actin, microtubules and cortactin [27] [28] [29] [30] , which raises the possibility that MYLK can regulate integrin function by organizing the cytoskeletal architecture 9 . In this study, we demonstrate that the nonmuscle MYLK was required for neutrophil adhesion to and migration across the endothelium in a lipopolysaccharide (LPS)-induced model of lung injury. Unexpectedly, this function of MYLK was mostly independent of myosin II activity. Instead, we found that MYLK was required for actin polymerization and the full activation of b 2 integrins and thus mediated neutrophil transendothelial migration. Our results demonstrate that MYLK's binding to and activation of the tyrosine kinases c-Src and Pyk2 was crucial for the recruitment of Pyk2 to b 2 integrins. These observations suggest that MYLK mediates a regulatory pathway in neutrophils during innate immune responses. This pathway may provide a therapeutic target for the prevention and treatment of inappropriate neutrophil migration and sequestration in conditions such as sepsis-induced lung inflammation and injury.
RESULTS

MYLK is required for neutrophil transmigration
Mylk -/-mice are less susceptible to LPS-induced acute lung injury 10 . We found that after injection of LPS, Mylk -/-mice had a smaller increase in lung vascular permeability and edema formation than did wild-type mice ( Supplementary Fig. 1 online) . As nonmuscle MYLK is expressed both in endothelial cells and neutrophils ( Supplementary  Fig. 2 online) , the protective effect in Mylk -/-mice could have been the result of either less permeability of the endothelial barrier or impaired migratory ability of neutrophils. To distinguish the function of nonmuscle MYLK in neutrophil transmigration from that in endothelial barrier regulation, we used an ex vivo lung injury assay, perfusing isolated wild-type mouse lungs with neutrophils from Mylk -/-or wild-type mice 31 . We measured the lung microvessel filtration coefficient and gain of lung wet weight to assess the vascular permeability of lungs and edema formation, respectively. The group with Mylk -/-neutrophil perfusion had significantly lower microvessel filtration coefficient values and wet weight gain (by about 50% in each case) than did the group perfused with wild-type neutrophils in the presence of LPS (Fig. 1a,b) . As we used wild-type lungs as recipients in both groups, the difference represents the impaired ability of Mylk -/-neutrophils to cause lung injury. These functional studies demonstrate that MYLK in neutrophils is a critical factor mediating LPS-induced lung injury.
To examine lung neutrophil sequestration in these studies, we perfused wild-type lungs with 111 In-oxine-labeled neutrophils along with LPS, the bacterial chemoattractant fMLP (N-formyl-methionylleucyl-phenylalanine) or saline (control). After washing out unbound neutrophils from vessels, we measured the g-radioactivity of lung tissue, which represented the resident neutrophils. Although both LPS and fMLP stimulated the uptake of wild-type neutrophils in lungs, the uptake of Mylk -/-neutrophils was significantly lower (by about 40% and 90% in response to each stimulus, respectively; Fig. 1c) .
Neutrophil adhesion and migration are two critical events during the transendothelial migration of neutrophils; thus, we addressed by in vitro assay whether either step was affected for Mylk -/-neutrophils. We purified wild-type and Mylk -/-neutrophils and added them to cultured wild-type mouse lung vascular endothelial cells. After washing away nonadherent cells, we counted residual neutrophils to determine adhesive activity. With LPS stimulation, the number of adherent wild-type neutrophils was sixfold higher than without (Fig. 1d) , whereas the number of adherent Mylk -/-neutrophils was about 50% less than wild type (Fig. 1d) . We analyzed neutrophil migration by Transwell assay with two chambers separated by a monolayer of endothelial cells. We applied LPS-primed wild-type or Mylk -/-neutrophils to the upper chamber and the chemoattractant fMLP to the lower chamber. We assessed cells that had migrated into the lower chamber and attached to the basal side of the filter after 4 h of incubation. The transendothelial migration of LPS-primed wildtype neutrophils was sixfold higher after fMLP stimulation relative to that with LPS only. However, the fMLP-induced migration of LPS-primed Mylk -/-neutrophils was about 55% that of wild-type neutrophils (Fig. 1e) . We also consistently noted less LPS-induced transalveolar migration of neutrophils in Mylk -/-mice than in wildtype mice (Fig. 1f ). These data demonstrate that both adhesion to endothelial cells and migration across the pulmonary endothelium are substantially impaired in Mylk -/-neutrophils.
We then compared the migratory activity of wild-type and Mylk -/-neutrophils after adherence to a fibrinogen-coated surface in vitro. Wild-type neutrophils after fMLP stimulation migrated in a more linear way with fewer turns. Mylk -/-neutrophils were still able to polarize and migrate, but they frequently changed direction (Supplementary Fig. 3a,b online) , which suggested involvement of MYLK in stabilizing the neutrophil leading edge. The MYLK-deficient neutrophils also had migrated faster ( Supplementary Fig. 3c ). These data collectively show that MYLK is an important determinant of neutrophil migration both in vivo and in vitro.
Myosin II is activated in the absence of MYLK As MLC is the only known substrate for MYLK (MYLK phosphorylates MLC at Thr18 and Ser19) 6, 7 , we next determined whether MYLK regulates the adhesion and migration of neutrophils secondary to activation of MLC. We assessed MLC activation with an antibody that recognizes the phosphorylated subunit of MLC (p19-MLC). In wild-type lungs and neutrophils, p19-MLC was 1.5-fold higher after LPS stimulation (Fig. 2a,b) . Although basal p19-MLC was slightly lower in Mylk -/-lungs ( Fig. 2a) and neutrophils ( Fig. 2b) , MLC was activated after LPS stimulation to amounts similar to those of wildtype. We obtained similar results with fMLP stimulation (Supplementary Fig. 4 online). The question arose of whether MLC is activated by the smooth-muscle MYLK isoform, which is also present in Mylk -/-mice. However, we noted that Mylk -/-neutrophils showed little MYLK activity after LPS stimulation ( Supplementary Fig. 5 online). Thus, MYLK was not required for LPS-or fMLP-induced MLC phosphorylation, and the phenotype resulting from MYLK deletion was not mediated by MLC signaling. These results indicate alternative functions for MYLK in mediating neutrophil adhesion and migration.
That hypothesis was supported by morphological and functional studies of myosin II and MYLK. In polarized neutrophils, active myosin II (as visualized by staining with antibody to p19-MLC (anti-p19-MLC)) accumulated in the rear of cells 32 (Fig. 2c) . In contrast, MYLK was located mainly at the leading edge of polarized neutrophils (Fig. 2c) . In addition to the distinct subcellular distribution of MYLK, loss of function of myosin II or MYLK resulted in different cell migration. Blocking myosin II activity with the inhibitor blebbistatin 33 impaired the neutrophil rear contraction, as shown by noncontracted long tails 32 . However, Mylk -/-neutrophils had normal rear contraction with accumulation of MLC at the trailing edges during migration ( Supplementary Figs. 3 and 6 online) . Moreover, both Mylk -/-neutrophils and wild-type neutrophils treated with the MYLK inhibitor ML-7 showed less adhesion to the endothelium (Figs. 1d and 2d) . In contrast, the myosin II inhibitor blebbistatin and the Rho kinase inhibitor Y27632 (which blocks myosin II activation 34, 35 ) resulted in enhanced neutrophil adhesion (Fig. 2d) .
Myosin II is known to mediate the 'backness' signal regulated by the RhoA and Rho kinase pathway, which prevents lateral pesudopod formation during neutrophil migration 32 . Inhibition of the 'backness' signal can enhance the 'frontness' signal, such as F-actin formation 32, 36 . Wild-type neutrophils treated with blebbistatin or Y27632 had much more actin polymerization before and after LPS stimulation ( Supplementary Fig. 7a online) . In contrast, F-actin content was lower in Mylk -/-neutrophils than in wild-type neutrophils (40% less; Supplementary Fig. 7b ) and was lower in wild-type neutrophils after ML-7 treatment (40% less than no treatment; Supplementary  Fig. 7a ), which suggested that MYLK does not act as a 'backness' signal and has a function opposite to that of myosin II in cytoskeleton assembly. Thus, MYLK and myosin II have distinct subcellular localizations and different functions during neutrophil migration, which indicates an important function for MYLK in regulating neutrophil migration by a pathway other than through MLC phosphorylation.
MYLK is required for b 2 integrin activation in neutrophils
As MYLK regulation of neutrophil adhesion and migration is independent of MLC phosphorylation, we next explored a previously unknown function for MYLK. The b 2 integrins are the main cell surface adhesion molecules required for the adhesion of neutrophils to the endothelium 14 . Because loss MYLK function led to impaired adhesive ability and migration as well as less tissue sequestration of neutrophils ( Fig. 1c-e) , we examined the possibility that b 2 integrin function was disrupted in Mylk -/-neutrophils. On surfaces coated with ICAM-1 (a ligand for b 2 integrins), wild-type neutrophils adhered and spread with clustering of b 2 integrin, as detected with antibody to a M , an a-subunit of b 2 integrins (Fig. 3a,b) . In contrast, 50% fewer Mylk -/-neutrophils adhered to ICAM-1 in the presence of LPS with much less spreading (Fig. 3a,b) , which indicated that b 2 integrin function was impaired in Mylk -/-neutrophils. To assess the activation of b 2 integrins, we used a soluble ICAM-1 binding assay. We incubated freshly isolated wild-type and Mylk -/-neutrophils with Fc-tagged ICAM-1 and analyzed them by flow cytometry. LPS-induced ICAM-1 binding in the presence of Mn 2+ was significantly lower in Mylk -/-neutrophils than in wild-type neutrophils (Fig. 3c) , which indicated that MYLK is required for the activation of b 2 integrin. To determine whether the lower integrin activation was due to less surface expression of integrin, we assessed LPS-induced cell surface expression of a L , a M and b 2 on wild-type and Mylk -/-neutrophils. LPS increased the expression of all three integrin molecules at the surface of Mylk -/-neutrophils; such expression was similar to that of wild-type neutrophils (Fig. 3d) .
MYLK is required for activation of Src and Pyk2
Integrin activation can be divided into two stages [18] [19] [20] [21] signals then activate tyrosine kinases such as c-Src, Syk and Pyk2, thereby fully activating integrins, possibly through additional actin polymerization and reinforced integrin-cytoskeleton interaction [18] [19] [20] [21] .
To explore how MYLK functions in the mechanism of integrin activation, we first studied whether crosstalk of MYLK with these tyrosine kinases regulated actin polymerization. We assessed activation of c-Src, Syk and Pyk2 with phosphorylation-specific antibodies in wild-type and Mylk -/-neutrophils. All three tyrosine kinases were phosphorylated in wild-type neutrophils after LPS challenge (Fig. 4a) . However, phosphorylation of c-Src and Pyk2 was about 80% and 60% lower, respectively, in Mylk -/-neutrophils, whereas phosphorylation of Syk was only slightly lower ( Fig. 4a) , which indicated that MYLK is required for the activation of c-Src and Pyk2. Furthermore, our functional data showed that blocking c-Src activity with its inhibitor, PP2, resulted in less adhesion of neutrophils to the endothelium (Fig. 2d) and less F-actin formation ( Supplementary  Fig. 7a ), consistent with the results obtained with Mylk -/-neutrophils ( Fig. 1d and Supplementary Fig. 7b) . MYLK has been shown to bind to c-Src 37 , and here we detected that MYLK was also associated with Pyk2 in both coimmunostaining and coimmunoprecipitation assays (Fig. 4b) . Notably, although both c-Src and Pyk2 bound to b 2 integrins in wild-type neutrophils (Fig. 4c) , the Pyk2-b 2 integrin interaction but not the c-Src-b 2 integrin interaction was disrupted in Mylk -/-neutrophils (Fig. 4c) . We further explored how MYLK regulates Pyk2 activation by in vitro assay. We found that MYLK interacted with Pyk2 directly and phosphorylated Pyk2 in vitro ( Supplementary Fig. 8a ,b online) and that ML-7 partially blocked Pyk2 activation ( Supplementary Fig. 8c ), which indicated that the kinase activity of MYLK and the MYLK-Pyk2 interaction may both be required for Pyk2 activation. These results collectively demonstrate that MYLK is critical for the activation both c-Src and Pyk2 and is required for the recruitment of Pyk2 to the b 2 integrin complex.
MYLK regulates the b 2 integrin-cytoskeleton interaction
The interaction of integrin with F-actin through actin-associated proteins such as talin is critical for strong integrin-cytoskeleton connections and integrin activation 18 . Pyk2 has been shown to activate the small Rho GTPase Cdc42 by inhibiting PSGAP (a Rho GTPase-activating protein), thus promoting actin polymerization 38 . We found less F-actin formation in Mylk -/-neutrophils (Supplementary Fig. 7b) , which suggested that Pyk2-mediated actin polymerization and b 2 integrin-cytoskeleton interactions could be a chief signaling mechanism 'downstream' of MYLK responsible for neutrophil transmigration.
To test that hypothesis, we determined whether MYLK participates in mediating b 2 integrin-cytoskeleton assembly. Although b 2 integrins bound to talin in wild-type neutrophils 15 , this binding was much lower in Mylk -/-neutrophils (Fig. 5a) . We obtained similar results for the interaction of b 2 integrin with another actin-associated protein, a-actinin (Fig. 5b) . However, we did not detect any interaction of MYLK with b 2 integrins, talin or a-actinin in wild-type neutrophils (data not shown). Thus, MYLK may indirectly regulate the interaction of b 2 integrins and actin-associated proteins, possibly through Pyk2-mediated actin polymerization. Our results have collectively shown that MYLK is required for the activation of c-Src and Pyk2 during the transendothelial migration of neutrophils and for the recruitment of Pyk2 to the b 2 integrin complex. The activation of tyrosine kinases in turn is essential in the mechanism of actin polymerization; it reinforces the b 2 integrin-cytoskeleton connection and fully activates b 2 integrins, a crucial requirement for the adhesion and transmigration of neutrophils ( Supplementary Fig. 9 online) .
DISCUSSION
The nonmuscle isoform of MYLK is fundamental in the regulation of endothelial barrier function 11, 12 . Studies have also shown that Mylk -/-mice are less susceptible to endotoxin-induced lung injury 10 . However, such studies have not distinguished the function of MYLK in neutrophils from that in endothelial cells. In our study here, the use of an ex vivo sepsis model and isolated neutrophils allowed us to address the function of MYLK in the mechanism of neutrophil transmigration in lungs. We noted that loss of MYLK function inhibited neutrophil sequestration and transalveolar migration in wild-type lungs and, moreover, the lower sequestration of Mylk -/-neutrophils resulted in less of a neutrophil-mediated increase in pulmonary vascular permeability and lung edema formation. Our findings have shown that activation of MYLK in neutrophils resulting in the adhesion of neutrophils to pulmonary vascular endothelium is essential in neutrophil-mediated inflammatory lung injury.
Although MLC is the only known substrate of MYLK, our findings have indicated that the function of MYLK in regulating neutrophil adhesion and migration is not mediated by MLC phosphorylation. We found that MLC could still be phosphorylated in Mylk -/-neutrophils. Although the smooth-muscle isoform of MYLK is also present in Mylk -/-mice, we found that Mylk -/-neutrophils showed little MYLK activity after LPS stimulation, which suggests that activation of MLC in Mylk -/-mice is not mediated by the smooth-muscle isoform MYLK. It is possible, however, that MLC phosphorylation in neutrophils is regulated by other kinases such as Rho kinase and Zip kinase 34, 35, 39 . MLC and MYLK also showed distinct subcellular localizations and different functions during neutrophil transmigration, consistent with the biochemical data. MYLK was localized to the leading edge of polarized neutrophils, whereas active MLC accumulated at the trailing edge. Furthermore, blocking myosin II and MYLK produced opposite effects on both neutrophil adhesion and actin polymerization. These data collectively indicate that MYLK has a MLC phosphorylation-independent function that mediates neutrophil adhesion and migration during LPS-induced lung injury.
MYLK, in addition to having a kinase domain, contains sites that bind to cytoskeletal proteins and tyrosine kinases 27, 29, 37 , which suggests that MYLK may function as an adaptor protein through these interactions. We have provided evidence here that in addition to binding to the tyrosine kinase c-Src, MYLK also bound to Pyk2. MYLK interacted with Pyk2 directly and phosphorylated Pyk2 in vitro, and ML-7 partially blocked Pyk2 activation, which indicates that the kinase activity of MYLK and the MYLK-Pyk2 interaction may be both required for Pyk2 activation. Nevertheless, it remains unclear whether MYLK can directly phosphorylate Pyk2 in vivo. It has been reported that activation of Pyk2 activates Cdc42 and subsequently induces actin polymerization 38 . We noted that loss of MYLK also abolished Cdc42 activation (data not shown) as well as actin polymerization stimulated by LPS. Thus, MYLK may be required for the activation of a tyrosine kinase-Cdc42-actin signaling pathway mediating neutrophil adhesion and migration.
The b 2 integrins are the main adhesion molecules expressed in neutrophils and are responsible for mediating the adhesion of neutrophils to the endothelium. Our data showed lower activation of b 2 integrins in Mylk -/-neutrophils. In the two-step model of integrin activation [18] [19] [20] [21] , both c-Src and Pyk2 are the 'outside-in' signals activated after integrin-matrix binding and thereby promote actin polymerization 24, 38, 40 . The additional actin polymerization reinforces the integrin-cytoskeleton interaction, which sustains b 2 integrins in the high-affinity and high-avidity state, reflecting the full activation of integrins [18] [19] [20] [21] . Here we have shown that in addition to being required for integrin-matrix binding, MYLK is also required for the activation of c-Src and Pyk2, and it thereby contributes to a later stage of b 2 integrin activation through the recruitment and activation of Pyk2 to the integrin complex. In this model, it remains unclear how MYLK regulates Src, although our data have shown that Src activation depended on the presence of MYLK. Src is not a substrate for MYLK, as ML-7 did not inhibit Src activation (data not shown). Src has been shown to directly phosphorylate MYLK 37 , but it is also possible, as evident from our results, that MYLK can itself regulate Src through a feedback mechanism.
Although MYLK is known as myosin II regulatory light-chain kinase, we have identified here an MLC phosphorylation-independent function for MYLK in complex with c-Src and Pyk2. This function of MYLK was essential for neutrophil transmigration during sepsisinduced lung injury. In contrast to myosin II, which is known as a 'backness' molecule responsible for rear contraction, MYLK functions as a 'frontness' molecule that accumulates at the front of neutrophils, where it is responsible for actin polymerization and the full activation of b 2 integrins. animal use. Mouse neutrophils were purified from mouse bone marrow and peripheral venous blood with a discontinuous Percol gradient as described with some modifications 41 . This procedure yielded polymorphonuclear neutrophil (PMN) purity of over 95% and viability of over 95%, as assessed by Trypan blue exclusion and analysis of cytospin preparations (Shandon) stained with the Hema 3 system (Fisher) 31 . Culture of neutrophil-like dHL60 cells and transfection were done as described 32 . MYLK cDNA was from Open Biosystems. Pyk2 cDNA was a gift from X. Zhu. Antibodies to MYLK were from Sigma (M7905) and Abgent (AP79669). Antibodies to p19-MLC (3671) and to phosphorylated c-Src (2113), Pyk2 (3291) and Syk (2715), as well as purified glutathione S-transferase-MYLK (Gly1425-Ser1776), were from Cell Signaling. Pyk2 protein was from Millipore.
Lung injury and neutrophil sequestration ex vivo. The pulmonary microvessel filtration coefficient and increases in lung wet weight were assessed as described 31 . For analysis of neutrophil sequestration, isolated bone marrow neutrophils were labeled with 111 In-labeled oxine (Amersham) as described 42 . Neutrophils (1 Â 10 6 ) were infused over 5 min with a syringe pump into the pulmonary artery line of the lung preparation, followed by a 30-minute washout period. Venous effluent samples were collected at 5-minute intervals and radioactivity was measured. The number of accumulating radiolabeled neutrophils per gram of dry lung was calculated at the end of the washout period.
MYLK activity assay. The activation of MYLK was measured in total cell lysates as described 43 . Cells were suspended in ice-cold kinase buffer (40 mM HEPES, pH 7.0, 5 mM Mg acetate, 0.55 mM CaCl 2 and 0.1% (vol/vol) Tween-80) containing freshly added 1 mM Na 3 VO 4 , 5 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml of pepstatin, 10 mg/ml of leupeptin, 10 mg/ml of aprotinin and 100 mg/ml of soybean trypsin inhibitor, then were disrupted by a cycle of freezing and thawing. Samples were sonicated with a probe twice for 12 s each on ice and were centrifuged with a microfuge. MYLK activity was assessed in supernatants of cell lysates in the presence or absence of substrate. A saturating concentration of 300 mM substrate was used for the MYLK activity assay. Reaction mixture containing substrate peptide or buffer plus 5 mCi [g-32 P]ATP and 0.5 mM unlabeled ATP was added to each tube and samples were incubated for 10 min at 30 1C. Reactions were stopped by filtration through Whatman P81 paper. After being washed, filters were added to scintillation fluid and radioactivity was measured in a scintillation counter (Wallac). 'Blanks' were assay samples without substrate.
F-actin content of neutrophils. F-actin was measured in neutrophils as described with some modifications 44 . Cells were stimulated for various times at 37 1C with LPS (Escherichia coli 0111:B4; EMD Chemicals) or fMLP (Sigma). Cells were immediately fixed for 30 min at 25 1C with 3.7% (vol/vol) paraformaldehyde in PBS and were washed with PBS. Cells were simultaneously made permeable and stained for 30 min at 37 1C in the dark with a fresh mixture of L-a-lysophosphatidylcholine palmitoyl (0.5 mg/ml; Sigma) and N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-phallacidin (0.1 mg/ml; Molecular Probes). After being stained, samples were washed and resuspended in PBS. F-actin was measured with fluorescein phalloidin (Invitrogen) with a Triad LT plate reader at excitation of 495 nm and an emission of 520 nm (Dynex Technologies).
Immunostaining and confocal microscopy. Freshly isolated neutrophils (2 Â 10 6 ) added to coverslips coated with fibrinogen (10 mg/ml) were challenged for various times at 37 1C with LPS (1 mg/ml; E. coli 0111:B4; EMD Chemicals). Cells were then fixed and made permeable and were stained sequentially with the appropriate antibodies. Images for confocal microscopy were obtained with a Zeiss LSM 510 microscope with excitation laser lines of 488 nm and 543 nm.
Neutrophil adhesion to endothelial cells and transendothelial migration.
Mouse lung vascular endothelial cells were isolated 45 and grown to confluence in 96-well gelatin-coated plates. Neutrophils loaded with calcein (acetoxymethyl ester) were added to mouse lung vascular endothelial cells and PMN adhesion to and migration on endothelial cells were assayed as described 45 .
Immunoprecipitation and immunoblot analysis. For immunoblot analysis, lysates were prepared as described 45 . Phosphorylation of MLC was measured as described 46 . For densitometry, the optical density of bands on autoradiograms was assessed with scanned autoradiograph films and the National Institutes of Health Image program.
Statistical analysis. Statistical comparisons were made with the two-tailed Student's t-test. Differences in mean values were considered significant at a P value of less than 0.05.
Accession codes. UCSD-Nature Signaling Gateway (http://www.signalinggateway.org): A000026 and A001952.
